Literature DB >> 6818144

Induction of phagocytic inhibitory activity in cats with chronic Pseudomonas aeruginosa pulmonary infection.

G B Winnie, J D Klinger, J M Sherman, M J Thomassen.   

Abstract

Chronic pulmonary infection has been established in cats by repeated intrapulmonary inoculation of viable Pseudomonas aeruginosa enmeshed in agarose beads. In the serum of all chronically infected animals, a substance(s) developed which inhibited phagocytosis of P. aeruginosa by normal cat alveolar macrophages. Phagocytosis was measured by incubating macrophage monolayers (5 X 10(5) alveolar macrophages) for 20 min in the presence of 3H-labeled bacteria and 5% serum from control or infected animals. Inhibitory activity developed 4 to 16 weeks after initial infection, and inhibition of phagocytosis of P. aeruginosa in the presence of infected cat serum ranged from 30 to 79%. After inhibitory activity developed, it persisted throughout the remainder of the experiment in each animal. The activity was specific for P. aeruginosa of the infecting serotype and did not affect phagocytosis of gram-positive organisms. Inhibitory activity was unchanged by heating serum at 56 degrees C for 30 min. We have previously described a P. aeruginosa-specific, heat-stable, phagocytosis-inhibitory activity in the serum of patients with cystic fibrosis. Since inhibitory activity also develops in cats with chronic P. aeruginosa pulmonary infection, such activity may not be a primary intrinsic abnormality in patients with cystic fibrosis. The animal model described here offers a system for following the development of and for characterization of the P. aeruginosa-specific phagocytosis-inhibitory activity.

Entities:  

Mesh:

Year:  1982        PMID: 6818144      PMCID: PMC347861          DOI: 10.1128/iai.38.3.1088-1093.1982

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  9 in total

1.  Studies on pulmonary alveolar macrophages from the normal rabbit: a technique to procure them in a high state of purity.

Authors:  Q MYRVIK; E S LEAKE; B FARISS
Journal:  J Immunol       Date:  1961-02       Impact factor: 5.422

Review 2.  Cystic fibrosis.

Authors:  R E Wood; T F Boat; C F Doershuk
Journal:  Am Rev Respir Dis       Date:  1976-06

3.  Pulmonary host defenses. I. Analysis of protein and lipids in bronchial secretions and antibody responses after vaccination with pseudomonas aeruginosa.

Authors:  H Y Reynolds; R E Thompson
Journal:  J Immunol       Date:  1973-08       Impact factor: 5.422

4.  Pseudomonas: the compromised host.

Authors:  R E Wood
Journal:  Hosp Pract       Date:  1976-08

Review 5.  Research in cystic fibrosis (third of three parts).

Authors:  P A di Sant'Agnese; P B Davis
Journal:  N Engl J Med       Date:  1976-09-09       Impact factor: 91.245

6.  A rat model of chronic respiratory infection with Pseudomonas aeruginosa.

Authors:  H A Cash; D E Woods; B McCullough; W G Johanson; J A Bass
Journal:  Am Rev Respir Dis       Date:  1979-03

7.  Inhibitory effect of cystic fibrosis serum on pseudomonas phagocytosis by rabbit and human alveolar macrophages.

Authors:  M J Thomassen; B Boxerbaum; C A Demko; P J Kuchenbrod; D G Dearborn; R E Wood
Journal:  Pediatr Res       Date:  1979-09       Impact factor: 3.756

8.  Multiple of isolates of Pseudomonas aeruginosa with differing antimicrobial susceptibility patterns from patients with cystic fibrosis.

Authors:  M J Thomassen; C A Demko; B Boxerbaum; R C Stern; P J Kuchenbrod
Journal:  J Infect Dis       Date:  1979-12       Impact factor: 5.226

9.  Cystic fibrosis pseudomonas opsonins. Inhibitory nature in an in vitro phagocytic assay.

Authors:  R B Fick; G P Naegel; R A Matthay; H Y Reynolds
Journal:  J Clin Invest       Date:  1981-10       Impact factor: 14.808

  9 in total
  9 in total

1.  Bronchoalveolar lavage in the cat: cytological findings.

Authors:  G M McCarthy; P J Quinn
Journal:  Can J Vet Res       Date:  1989-07       Impact factor: 1.310

Review 2.  Inflammation in the lung in cystic fibrosis. A vicious cycle that does more harm than good?

Authors:  M Berger
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

3.  Association with phagocytic inhibition of anti-Pseudomonas aeruginosa immunoglobulin G antibody subclass levels in serum from patients with cystic fibrosis.

Authors:  T R Shryock; J S Mollé; J D Klinger; M J Thomassen
Journal:  J Clin Microbiol       Date:  1986-03       Impact factor: 5.948

Review 4.  Antibody-Dependent Enhancement of Bacterial Disease: Prevalence, Mechanisms, and Treatment.

Authors:  Von Vergel L Torres; Carrie F Coggon; Timothy J Wells
Journal:  Infect Immun       Date:  2021-03-17       Impact factor: 3.441

5.  Pulmonary cellular response to chronic irritation and chronic Pseudomonas aeruginosa pneumonia in cats.

Authors:  M J Thomassen; J D Klinger; G B Winnie; R E Wood; C Burtner; J F Tomashefski; J G Horowitz; B Tandler
Journal:  Infect Immun       Date:  1984-09       Impact factor: 3.441

Review 6.  Cystic fibrosis. Infection and immunity to Pseudomonas.

Authors:  R U Sorensen; R L Waller; J D Klinger
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

7.  Anti-Pseudomonas aeruginosa IgG subclass titers in patients with cystic fibrosis: correlations with pulmonary function, neutrophil chemotaxis, and phagocytosis.

Authors:  R G Cowan; G B Winnie
Journal:  J Clin Immunol       Date:  1993-09       Impact factor: 8.317

Review 8.  From in vitro to in vivo Models of Bacterial Biofilm-Related Infections.

Authors:  David Lebeaux; Ashwini Chauhan; Olaya Rendueles; Christophe Beloin
Journal:  Pathogens       Date:  2013-05-13

9.  A lung segmental model of chronic Pseudomonas infection in sheep.

Authors:  David Collie; John Govan; Steven Wright; Elisabeth Thornton; Peter Tennant; Sionagh Smith; Catherine Doherty; Gerry McLachlan
Journal:  PLoS One       Date:  2013-07-09       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.